阿尔茨海默病的早期诊断和治疗：新的定义和挑战。
Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges.
机构信息
Laboratório de Neurociências (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
出版信息
Braz J Psychiatry. 2020 Aug;42(4):431-441. doi: 10.1590/1516-4446-2019-0735. Epub 2020 Jan 24.
Abstract
The prevalence of Alzheimer's disease (AD), a progressive neurodegenerative disorder, is expected to more than double by 2050. Studies on the pathophysiology of AD have been changing our understanding of this disorder and setting a new scenario for drug development and other therapies. Concepts like the "amyloid cascade" and the "continuum of AD," discussed in this article, are now well established. From updated classifications and recommendations to advances in biomarkers of AD, we aim to critically assess the literature on AD, addressing new definitions and challenges that emerged from recent studies on the subject. Updates on the status of major clinical trials are also given, and future perspectives are discussed.
摘要
阿尔茨海默病（AD）是一种进行性神经退行性疾病，预计到 2050 年其患病率将增加一倍以上。AD 病理生理学的研究改变了我们对这种疾病的认识，并为药物开发和其他疗法设定了新的方案。本文讨论的“淀粉样蛋白级联”和“AD 连续谱”等概念现已得到广泛认可。从更新的分类和建议到 AD 生物标志物的进展，我们旨在对 AD 文献进行批判性评估，解决该主题的最新研究中出现的新定义和挑战。还提供了主要临床试验现状的更新，并讨论了未来的展望。
相似文献
1
Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges.阿尔茨海默病的早期诊断和治疗：新的定义和挑战。
Braz J Psychiatry. 2020 Aug;42(4):431-441. doi: 10.1590/1516-4446-2019-0735. Epub 2020 Jan 24.
2
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.临床前阿尔茨海默病：定义、自然史及诊断标准。
Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002.
3
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.了解疾病进展和改善阿尔茨海默病临床试验：阿尔茨海默病神经影像学倡议的最新重点。
Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13.
4
Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.阿尔茨海默病的影像学技术：在早期诊断和纵向监测中的应用综述。
Int J Mol Sci. 2021 Feb 20;22(4):2110. doi: 10.3390/ijms22042110.
5
Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges.基于纳米医学的技术和新型生物标志物在阿尔茨海默病诊断和治疗中的应用：从当前到未来的挑战。
J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x.
6
On the path to 2025: understanding the Alzheimer's disease continuum.通往2025之路：理解阿尔茨海默病连续体
Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5.
7
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架：迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
8
[Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].[阿尔茨海默病临床前期的定义及疾病修饰治疗]
Nihon Rinsho. 2016 Mar;74(3):438-41.
9
[Toward Preclinical Trials for Alzheimer's Disease].迈向阿尔茨海默病的临床前试验
Brain Nerve. 2017 Jul;69(7):711-722. doi: 10.11477/mf.1416200812.
10
Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria.用于临床诊断阿尔茨海默病的生物标志物：在诊断标准演变过程中的 CSF 生物标志物的作用。
Int J Mol Sci. 2022 Aug 2;23(15):8598. doi: 10.3390/ijms23158598.
引用本文的文献
1
From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer's Disease.从淀粉样蛋白到突触功能障碍：基于生物标志物的阿尔茨海默病见解
Curr Issues Mol Biol. 2025 Jul 22;47(8):580. doi: 10.3390/cimb47080580.
2
Multi-Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations.阿尔茨海默病治疗中的多靶点药物设计：新兴技术、优势、挑战与局限
Pharmacol Res Perspect. 2025 Aug;13(4):e70131. doi: 10.1002/prp2.70131.
3
Using Web-Based Continuing Education to Improve New Diagnoses of Alzheimer Disease in Claims Data: Retrospective Case-Control Study.利用基于网络的继续教育改善理赔数据中阿尔茨海默病的新诊断：回顾性病例对照研究。
JMIR Med Educ. 2025 May 22;11:e72000. doi: 10.2196/72000.
4
Recent Advancements in Neuroimaging-Based Alzheimer's Disease Prediction Using Deep Learning Approaches in e-Health: A Systematic Review.电子健康领域基于深度学习方法的神经影像学阿尔茨海默病预测研究新进展：一项系统综述
Health Sci Rep. 2025 May 5;8(5):e70802. doi: 10.1002/hsr2.70802. eCollection 2025 May.
5
Multi-Modal Fusion and Longitudinal Analysis for Alzheimer's Disease Classification Using Deep Learning.基于深度学习的阿尔茨海默病分类的多模态融合与纵向分析
Diagnostics (Basel). 2025 Mar 13;15(6):717. doi: 10.3390/diagnostics15060717.
6
Prevalence of ApoE Alleles in a Spanish Population of Patients with a Clinical Diagnosis of Alzheimer's Disease: An Observational Case-Control Study.西班牙临床诊断为阿尔茨海默病患者群体中载脂蛋白E等位基因的患病率：一项观察性病例对照研究
Medicina (Kaunas). 2024 Nov 25;60(12):1941. doi: 10.3390/medicina60121941.
7
Comparative Diagnostic Performance of Amyloid-β Positron Emission Tomography and Magnetic Resonance Imaging in Alzheimer's Disease: A Head-to-Head Meta-Analysis.阿尔茨海默病中淀粉样蛋白-β正电子发射断层扫描和磁共振成像的比较诊断性能：一项头对头的荟萃分析。
Brain Behav. 2024 Oct;14(10):e70111. doi: 10.1002/brb3.70111.
8
Deep learning techniques for Alzheimer's disease detection in 3D imaging: A systematic review.用于三维成像中阿尔茨海默病检测的深度学习技术：一项系统综述。
Health Sci Rep. 2024 Sep 18;7(9):e70025. doi: 10.1002/hsr2.70025. eCollection 2024 Sep.
9
Effects of Dance-Based Aerobic Training on Mental Health and Quality of Life in Older Adults with Mild Cognitive Impairment.基于舞蹈的有氧训练对轻度认知障碍老年人心理健康和生活质量的影响。
J Pers Med. 2024 Aug 9;14(8):844. doi: 10.3390/jpm14080844.
10
Melatonin improves cognitive dysfunction and decreases gliosis in the streptozotocin-induced rat model of sporadic Alzheimer's disease.褪黑素可改善链脲佐菌素诱导的散发性阿尔茨海默病大鼠模型中的认知功能障碍并减少胶质细胞增生。
Front Pharmacol. 2024 Jul 29;15:1447757. doi: 10.3389/fphar.2024.1447757. eCollection 2024.
本文引用的文献
1
Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.阿尔茨海默病的神经影像学：聚焦于淀粉样蛋白和tau PET。
Jpn J Radiol. 2019 Nov;37(11):735-749. doi: 10.1007/s11604-019-00867-7. Epub 2019 Sep 6.
2
Alzheimer's disease drug development pipeline: 2019.2019年阿尔茨海默病药物研发进程
Alzheimers Dement (N Y). 2019 Jul 9;5:272-293. doi: 10.1016/j.trci.2019.05.008. eCollection 2019.
3
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.全自动血浆检测作为阿尔茨海默病相关β-淀粉样蛋白状态筛查试验的性能
JAMA Neurol. 2019 Sep 1;76(9):1060-1069. doi: 10.1001/jamaneurol.2019.1632.
4
Neuroimaging Biomarkers for Alzheimer's Disease.神经影像学阿尔茨海默病生物标志物。
Mol Neurodegener. 2019 Jun 7;14(1):21. doi: 10.1186/s13024-019-0325-5.
5
Alzheimer disease and aducanumab: adjusting our approach.阿尔茨海默病与阿杜卡单抗：调整我们的方法。
Nat Rev Neurol. 2019 Jul;15(7):365-366. doi: 10.1038/s41582-019-0205-1.
6
Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease.与突触功能相关的改变的 microRNAs 作为阿尔茨海默病的潜在血浆生物标志物。
Alzheimers Res Ther. 2019 May 15;11(1):46. doi: 10.1186/s13195-019-0501-4.
7
Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.阿尔茨海默病的血浆生物标志物正在成为药物研发的重要工具：欧盟/美国 CTAD 工作组报告。
J Prev Alzheimers Dis. 2019;6(3):169-173. doi: 10.14283/jpad.2019.21.
8
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.抗 Tau 治疗阿尔茨海默病临床试验：来自欧盟/美国/CTAD 工作组的报告。
J Prev Alzheimers Dis. 2019;6(3):157-163. doi: 10.14283/jpad.2019.14.
9
Editorial: Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer's Disease.社论：基于tau蛋白的疗法：阿尔茨海默病之战中的替代方法
J Prev Alzheimers Dis. 2019;6(3):151-152. doi: 10.14283/jpad.2019.13.
10
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.边缘系统为主的年龄相关性 TDP-43 脑病（LATE）：共识工作组报告。
Brain. 2019 Jun 1;142(6):1503-1527. doi: 10.1093/brain/awz099.
Zotero 插件